PMID- 25251326
OWN - NLM
STAT- MEDLINE
DCOM- 20150501
LR  - 20220318
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 121
IP  - 3
DP  - 2015 Feb 1
TI  - Prognostic factors for advanced-stage human immunodeficiency virus-associated 
      classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and 
      dacarbazine plus combined antiretroviral therapy: a multi-institutional 
      retrospective study.
PG  - 423-31
LID - 10.1002/cncr.29066 [doi]
AB  - BACKGROUND: The treatment and outcomes of patients with human immunodeficiency 
      virus (HIV)-associated Hodgkin lymphoma (HL) continue to evolve. The 
      International Prognostic Score (IPS) is used to predict the survival of patients 
      with advanced-stage HL, but it has not been validated in patients with HIV 
      infection. METHODS: This was a multi-institutional, retrospective study of 229 
      patients with HIV-associated, advanced-stage, classical HL who received 
      doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus combination 
      antiretroviral therapy. Their clinical characteristics were presented 
      descriptively, and multivariate analyses were performed to identify the factors 
      that were predictive of response and prognostic of progression-free survival 
      (PFS) and overall survival (OS). RESULTS: The overall and complete response rates 
      to ABVD in patients with HIV-associated HL were 91% and 83%, respectively. After 
      a median follow-up of 5 years, the 5-year PFS and OS rates were 69% and 78%, 
      respectively. In multivariate analyses, there was a trend toward an IPS score >3 
      as an adverse factor for PFS (hazard ratio [HR], 1.49; P=.15) and OS (HR, 1.84; 
      P=.06). A cluster of differentiation 4 (CD4)-positive (T-helper) cell count <200 
      cells/muL was associated independently with both PFS (HR, 2.60; P=.002) and OS 
      (HR, 2.04; P=.04). The CD4-positive cell count was associated with an increased 
      incidence of death from other causes (HR, 2.64; P=.04) but not with death from 
      HL-related causes (HR, 1.55; P=.32). CONCLUSIONS: The current results indicate 
      excellent response and survival rates in patients with HIV-associated, 
      advanced-stage, classical HL who receive ABVD and combination antiretroviral 
      therapy as well as the prognostic value of the CD4-positive cell count at the 
      time of lymphoma diagnosis for PFS and OS.
CI  - (c) 2014 American Cancer Society.
FAU - Castillo, Jorge J
AU  - Castillo JJ
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, 
      Massachusetts.
FAU - Bower, Mark
AU  - Bower M
FAU - Bruhlmann, Jeremy
AU  - Bruhlmann J
FAU - Novak, Urban
AU  - Novak U
FAU - Furrer, Hansjakob
AU  - Furrer H
FAU - Tanaka, Paula Y
AU  - Tanaka PY
FAU - Besson, Caroline
AU  - Besson C
FAU - Montoto, Silvia
AU  - Montoto S
FAU - Cwynarski, Kate
AU  - Cwynarski K
FAU - Abramson, Jeremy S
AU  - Abramson JS
FAU - Dalia, Samir
AU  - Dalia S
FAU - Bibas, Michele
AU  - Bibas M
FAU - Connors, Joseph M
AU  - Connors JM
FAU - Furman, Michael
AU  - Furman M
FAU - Nguyen, Minh-Ly
AU  - Nguyen ML
FAU - Cooley, Timothy P
AU  - Cooley TP
FAU - Beltran, Brady E
AU  - Beltran BE
FAU - Collins, Jaime A
AU  - Collins JA
FAU - Vose, Julie M
AU  - Vose JM
FAU - Xicoy, Blanca
AU  - Xicoy B
FAU - Ribera, Josep-Maria
AU  - Ribera JM
CN  - HIV-Associated Hodgkin Lymphoma in the cART Era Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140923
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Anti-Retroviral Agents)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Dacarbazine/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - HIV Infections/*drug therapy/*pathology
MH  - Hodgkin Disease/*drug therapy/pathology/*virology
MH  - Humans
MH  - Lymphoma, AIDS-Related/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Vinblastine/administration & dosage
OTO - NOTNLM
OT  - CD4 count
OT  - Hodgkin lymphoma
OT  - and dacarbazine
OT  - antiretroviral therapy
OT  - bleomycin
OT  - doxorubicin
OT  - human immunodeficiency virus
OT  - vinblastine
EDAT- 2014/09/25 06:00
MHDA- 2015/05/02 06:00
CRDT- 2014/09/25 06:00
PHST- 2014/03/20 00:00 [received]
PHST- 2014/07/30 00:00 [revised]
PHST- 2014/08/19 00:00 [accepted]
PHST- 2014/09/25 06:00 [entrez]
PHST- 2014/09/25 06:00 [pubmed]
PHST- 2015/05/02 06:00 [medline]
AID - 10.1002/cncr.29066 [doi]
PST - ppublish
SO  - Cancer. 2015 Feb 1;121(3):423-31. doi: 10.1002/cncr.29066. Epub 2014 Sep 23.